Scientists at the CSIR‑Centre for Cellular and Molecular Biology (CSIR‑CCMB) have created an India‑specific scoring system to assess the severity of Sickle Cell Anaemia (SCA). The tool, called ISS1 and its simplified version ISS2, aims to guide treatment decisions more accurately than the internationally used Paediatric Severity Score (PSS).
Key Developments
- Study analysed records of 171 children (≤18 years) with SCA from Government Medical College & Hospital, Nagpur.
- Two senior paediatricians classified patients into mild, moderate and severe categories.
- Existing PSS matched expert assessment in only ~67 % of cases.
- Adding four Indian‑specific clinical features (recurrent transfusions, severe anaemia needing hospitalisation, acute febrile illnesses) raised concordance to ~83 % (ISS1).
- Replacing lab values with observable signs (ISS2) further improved agreement to ~85 % and correctly identified all mild cases.
Important Facts
Indian SCA patients often show a milder disease profile because of higher foetal haemoglobin levels. Complications common in African cohorts, such as leg ulcers, pulmonary hypertension and priapism, are rare in India. However, nutritional deficiencies, infections and environmental stressors can aggravate anaemia.
The most frequent complication observed was painful vaso‑occlusive crises. Frequent blood transfusions, severe anaemia and recurrent fever‑related illnesses were the main drivers of hospital admissions.
Exam Relevance
- Illustrates the need for population‑specific health tools, a recurring theme in health‑policy questions.
- Highlights the role of public research institutions like CSIR‑CCMB in addressing indigenous health challenges.
- Connects to the hydroxyurea dosage decisions, relevant for questions on drug policy and access.
- Provides a case study for the importance of adapting global guidelines to Indian realities, useful for GS3 and GS4 ethics‑based discussions on equity in healthcare.
Way Forward
Further validation of ISS1/ISS2 in larger, geographically diverse cohorts is essential before nationwide adoption. Training of clinicians in using the simplified ISS2 can reduce dependence on costly laboratory tests, benefitting low‑resource settings. The model can be adapted for other low‑ and middle‑income countries with similar genetic backgrounds, reinforcing India’s leadership in translational health research.